The increased number of IFN-act TN (T8) cells in the infected group, along with a significant enrichment of genes responding to type I IFN, suggest that we could use IFN-act TN cells as a potential drug treatment target for CE in the future. This evidence concerns the gene IFNA1 and cholesteryl ester measurement.